FDAs voluntary quality-audit pilot program set for spring rollout

The FDA has completed the setup of a new pilot program that will exempt medical device manufacturers from certain quality auditing for one year if they voluntarily submit satisfactory audit documentation. The program is set to launch June 5.

To get the exemption under the program, which debuted in draft form in May 2010, device makers must provide auditing records demonstrating compliance of their quality-management system with ISO 13485:2003, the international standard specifying conditions by which a quality-management system demonstrates a medical device manufacturer’s ability to consistently meet customer and regulatory requirements.

As the pilot program’s final guidance document puts it, the voluntarily submitted documentation needs to show evidence pointing to “minimal probability … that the establishment will produce nonconforming and/or defective finished devices.”

The guidance documents describing the program, Medical Device ISO 13485:2003 Voluntary Audit Report Submission Pilot Program, cover who is eligible for participation, what kinds of audit reports are acceptable for submission, how manufacturers should submit audit reports and what FDA will do with submissions.

The program is open to foreign as well as domestic manufacturers as long as they have been previously audited under a regulatory system implemented by a founding member of the Global Harmonization Task Force. These include the Canadian Medical Devices Conformity Assessment System, Notified Bodies designated by member states of the European Union, the Australian Therapeutics Goods Administration and the Japanese Ministry of Health, Labour and Welfare.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.